Validating multiparametric MRI for diagnosis and monitoring of prostate cancer in patients for active surveillance

Sahibzada, Iqbal; Batura, Deepak; Hellawell, Giles

doi:10.1007/s11255-016-1212-4

Cited by 11 publications

(8 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a separate study of 298 patients by Park et al , 14% of AS-eligible patients without an identifiable lesion had their PCa upgraded on final pathology following radical prostatectomy, but just one was found to have a positive surgical margin and no patients had greater than either form of Gleason 7 disease ( 28 ). Sahibzada et al reached a similar conclusion in their retrospective cross-sectional validation study of 100 patients, and suggest mpMRI may have greater reliability in the post-TRUS biopsy surveillance setting ( 29 ).…”

Section: Reviewmentioning

confidence: 73%

MRI findings guiding selection of active surveillance for prostate cancer: a review of emerging evidence

Glaser¹,

Porter²,

Thomas³

et al. 2018

Transl. Androl. Urol.

View full text Add to dashboard Cite

Active surveillance (AS) for prostate cancer (PCa) is generally considered to be a safe strategy for men with low-risk, localized disease. However, as many as 1 in 4 patients may be incorrectly classified as AS-eligible using traditional inclusion criteria. The use of multiparametric magnetic resonance imaging (mpMRI) may offer improved risk stratification in both the initial diagnostic and disease monitoring setting. We performed a review of recently published studies to evaluate the utility of this imaging modality for this clinical setting. An English literature search was conducted on PubMed for original investigations on localized PCa, AS, and magnetic resonance imaging. Our Boolean criteria included the following terms: PCa, AS, imaging, MRI, mpMRI, prospective, retrospective, and comparative. Our search excluded publication types such as comments, editorials, guidelines, reviews, or interviews. Our literature review identified 71 original investigations. Among these, 52 met our inclusion criteria. Evidence suggests mpMRI improves characterization of clinically significant prostate cancer (csPCa) foci, and the enhanced detection and risk-stratification afforded by this modality may keep men from being inappropriately placed on AS. Use of serial mpMRI may also permit longer intervals between confirmatory biopsies. Multiple studies demonstrate the benefit of MRI-targeted biopsies. The use of mpMRI of the prostate offers improved confidence in risk-stratification for men with clinically low-risk PCa considering AS. While on AS, serial mpMRI and MRI-targeted biopsy aid in the detection of aggressive disease transformation or foci of clinically-significant cancer undetected on prior biopsy sessions.

show abstract

Section: Reviewmentioning

confidence: 73%

MRI findings guiding selection of active surveillance for prostate cancer: a review of emerging evidence

Glaser¹,

Porter²,

Thomas³

et al. 2018

Transl. Androl. Urol.

View full text Add to dashboard Cite

show abstract

“…The whole lungs of all patients in the present study underwent MRI scanning according to the manufacturer's protocol (Ingenia 1.5T CX; Philips Medical Systems, Inc., Bothell, WA, USA). The details of the principles and settings used for MRI scanning were described in a previous study (25).…”

Section: Methodsmentioning

confidence: 99%

Contrast‑enhanced magnetic resonance imaging with a novel nano‑size contrast agent for the clinical diagnosis of patients with lung cancer

Gao

Liu

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

Abstract. Recent studies have indicated that magnetic resonance imaging (MRI) efficiently diagnoses lung cancer. However, the efficacy of MRI in diagnosing lung cancer requires improving for patients in the early stage of the disease. In the present study, a novel nano-sized contrast agent of chistosan/Fe 3 O 4 -enclosed bispecific antibodies (BsAbCENS) was introduced, which targeted carcino-embryonic antigen (CEA) and neuron-specific enolase (NSE) in lung cancer cells. The diagnostic efficacy of contrast-enhanced MRI with BsAbCENS (CEMRI-BsAbCENS) was investigated in a total of 182 patients with suspected lung cancer who had high serum levels of CEA and NSE. BsAbCENS was administered by pulmonary inhalation prior to the MRI scan. The results revealed that CEA and NSE were overexpressed in human lung cancer cell lines. BsAbCENS bound with CEA and NSE on the surface of human lung cancer cells and produced a higher signal intensity than MRI alone for the diagnosis of patients with lung cancer. The diagnostic data revealed that CEMRI-BsAbCENS diagnosed 124/182 lung cancer cases, whereas CEMRI only diagnosed 98/182, which was significantly less (P<0.01). In addition, the survival rate of patients with lung cancer diagnosed by CEMRI-BsAbCENS was significantly higher than the mean 5-year survival rate (P<0.01). Furthermore, the pharmacodynamics demonstrated that BsAbCENS was metabolized within 24 h. The results of the present study indicate that the efficacy and accuracy of lung cancer diagnosis are improved by CEMRI-BsAbCENS. In conclusion, these results provide a potential novel protocol for the diagnosis of tumors in patients with suspected early stage lung cancer.

show abstract

“…The whole heart in all of the patients was subjected to MRI scanning according to the manufacturer's protocol. The details of principles and settings of MRI were described in a previous study ( 20 ). MRI processes included T1 and T2 parametric mapping.…”

Section: Methodsmentioning

confidence: 99%

Combination of magnetic resonance imaging and targeted contrast agent for the diagnosis of myocardial infarction

Jiang-jun

Zhou

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

Myocardial infarction is one of the most common human cerebrovascular conditions and frequently leads to ischemic stroke. Evidence has indicated that magnetic resonance imaging (MRI) is a potential method for the diagnosis of patients with cardiovascular injury. However, the efficacy of MRI in diagnosing patients with myocardial infarction requires to be improved. In the present study, a novel nano-size contrast agent, a chitosan/Fe3O4-enclosed albumin (CFEA), was introduced that was used to quantify blood volume and permeability in the infarcted myocardium. A total of 68 patients with suspected myocardial infarction were recruited to analyze the efficacy of MRI combined with CFEA (MRI-CFEA). All patients received diagnosis by MRI and MRI-CFEA. It was revealed that MRI-CFEA provided a higher signal intensity than MRI in the same patients. It was demonstrated that the diagnostic efficacy of MRI-CFEA for patients with myocardial infarction was higher than that of MRI (P<0.05). By MRI-CFEA, 50/68 of cases with myocardial infarction were diagnosed, providing a significantly higher diagnostic rate compared with the 38/68 of cases diagnosed by contrast-enhanced MRI (P<0.01). MRI-CFEA successfully discriminated the infarcted regions based on a decreased fractional blood volume and increased permeability-surface (PS) area product in the infarcted myocardium. A pharmacodynamics analysis indicated that CFEA was eliminated within 24 h in all individuals. In conclusion, the present study provided a novel method to diagnose infarcted myocardium for patients with myocardial infarction, providing an imaging biomarker for the assessment of endothelial dysfunction in the clinic.

show abstract

Validating multiparametric MRI for diagnosis and monitoring of prostate cancer in patients for active surveillance

Cited by 11 publications

References 31 publications

MRI findings guiding selection of active surveillance for prostate cancer: a review of emerging evidence

MRI findings guiding selection of active surveillance for prostate cancer: a review of emerging evidence

Contrast‑enhanced magnetic resonance imaging with a novel nano‑size contrast agent for the clinical diagnosis of patients with lung cancer

Combination of magnetic resonance imaging and targeted contrast agent for the diagnosis of myocardial infarction

Contact Info

Product

Resources

About